Distal pancreatectomy with celiac axis resection for pancreatic body and tail cancer invading celiac axis.
10.4174/astr.2015.89.4.167
- Author:
Hyemin HAM
1
;
Sang Geol KIM
;
Hyung Jun KWON
;
Heontak HA
;
Young Yeon CHOI
Author Information
1. Departmet of Surgery, Kyungpook National University School of Medicine, Daegu, Korea.
- Publication Type:Original Article
- Keywords:
Pancreatic neoplasm;
Celiac artery;
Pancreatectomy
- MeSH:
Axis, Cervical Vertebra*;
Celiac Artery;
Humans;
Incidence;
Infarction;
Length of Stay;
Mortality;
Operative Time;
Pancreatectomy*;
Pancreatic Fistula;
Pancreatic Neoplasms;
Tail*
- From:Annals of Surgical Treatment and Research
2015;89(4):167-175
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Pancreatic body/tail cancer often involves the celiac axis (CA) and it is regarded as an unresectable disease. To treat the disease, we employed distal pancreatectomy with en bloc celiac axis resection (DP-CAR) and reviewed our experiences. METHODS: We performed DP-CAR for seven patients with pancreatic body/tail cancer involving the CA. The indications of DP-CAR initially included tumors with definite invasion of CA and were later expanded to include borderline resectable disease. To determine the efficacy of DP-CAR, the clinico-pathological data of patients who underwent DP-CAR were compared to both distal pancreatectomy (DP) group and no resection (NR) group. RESULTS: The R0 resection rate was 71.4% and was not statistically different compared to DP group. The operative time (P = 0.018) and length of hospital stay (P = 0.022) were significantly longer in DP-CAR group but no significant difference was found in incidence of the postoperative pancreatic fistula compared to DP group. In DP-CAR group, focal hepatic infarction and transient hepatopathy occurred in 1 patient and 3 patients, respectively. No mortality occurred in DP-CAR group. The median survival time (MST) was not statistically different compared to DP group. However, the MST of DP-CAR group was significantly longer than that of NR group (P < 0.001). CONCLUSION: In our experience, DP-CAR was safe and offered high R0 resection rate for patients with pancreatic body/tail cancer with involvement of CA. The effect on survival of DP-CAR is comparable to DP and better than that of NR. However, the benefits need to be verified by further studies in the future.
